Navigation Links
Insight into mechanisms of diabetes-induced microvascular disease reveals new therapies
Date:7/16/2008

New findings from Bristol scientists could lead to future treatments to prevent lower limb amputations in diabetes - which currently affect 100 people a week in the UK (source Diabetes UK).

The research from the University of Bristol is published online in Circulation Research and was funded by the British Heart Foundation (BHF) and the European Vascular Genomic Network of Excellence (EVGN).

Diabetes can have serious complications like gangrene and skin ulcers due to a restriction of blood supply to and healing capacity of the affected areas and this causes the dysfunction of cells lining the blood vessels. Legs and feet are often severely affected, and, after blood supply is obstructed or injury, the tissue seems to be unable to heal itself by growing new blood vessels making the situation much worse. If gangrenous wounds fail to heal amputation may be the only option.

Dr Costanza Emanueli, BHF Reader at Bristol University and colleagues at the Bristol Heart Institute have previously found that a group of growth factors - known as neurotrophins - play a role in the vascular system. Growth factors act on two completely different types of cellular receptors. One type, trk, mediates positive actions, such as survival and growing new blood vessels and the other, p75NTR, has not been comprehensively characterised.

In healthy blood vessels, the cells that line the blood vessels do not possess the p75NTR receptor, and the development of new blood vessels and healing of the obstructed blood supply and wounds is rapid. However, diabetes causes the cells lining the blood vessels to produce the p75NTR receptor, and prevents the growth of new blood vessels necessary for blood supply and healing of damaged tissue.

Dr Emanueli's group found that if they put the receptor gene into healthy blood vessel cells, the cells became dysfunctional. Equally, injecting the gene into healthy muscle and then restricting blood supply caused impaired healing following the injury identical to that seen in diabetes.

The final proof was to inhibit the p75NTR receptor in diabetic mice before restricting the blood supply to one of their "limbs". The researchers found that p75NTR inhibition enabled the limb to recover from the restricted blood flow and be well supplied with blood.

p75NTR acts by depressing the cell's normal signalling mechanisms that are necessary to stimulate the growth of new blood vessels. In its absence, this process proceeds normally.

Dr Emanueli said: "Our findings demonstrate the importance of understanding the individual factors responsible for such diabetes-induced complications. The data reveal that by suppressing the action of one particular gene, we can improve recovery of tissues following inadequate blood flow, and this opens up new avenues for its use to combat diabetes-induced vascular disease."


'/>"/>

Contact: joanne.fryer@bristol.ac.uk
joanne.fryer@bristol.ac.uk
44-117-331-7276
University of Bristol
Source:Eurekalert

Related medicine news :

1. Pitt-led research provides insight into development of congenital circulatory defects
2. MedInsights, Inc. Selects Douglas Young as VP - Sales & Product Development
3. Bacterial peptide provides new insight into common tumor suppressor
4. Circulating Tumor Cells Reveal Insights Into Lung Cancers
5. Leaders Develop Leaders: Insights from Global Benchmarking Councils 10th Annual Human Resources Conference
6. CVS Caremark to Present Insights on Redefining the Consumer Health Care Experience at AHIP Institute 2008
7. Parks Associates Analysts Present Insights on Broadband, Digital Content, Advertising, Home Systems, and Digital Health at CONNECTIONS(TM)
8. New molecular insight into amboebic dysentery
9. Molecular insight begins Trofex Phase 1 trial for detection of metastatic prostate cancer
10. New insight into RA patient priorities and motivators for clinical trial involvement
11. Molecular insight begins Trofex Ph. 1 trial for detection of metastatic prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Leading ... 2017 on May 30th and 31st at The Four Seasons Hotel Boston. ... in the life sciences, offering exclusive access to key decision makers who influence ...
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the first physician ... spinal cord stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as ... the first in Arkansas to introduce the most powerful SCS system and the only ...
(Date:5/26/2017)... ... ... A new analysis of community health data reveals that four out of the ... the average cost of healthcare rising and the U.S. senior population expected to double ... of where they live. An annual 2017 report looked at a variety of community ...
(Date:5/26/2017)... ... 26, 2017 , ... via seating is proud to partner ... chair specifically designed for clinical areas. Genie Copper Mesh is a crossover chair ... to provide customers with a game changing chair that is affordably priced,” Chas ...
(Date:5/26/2017)... ... May 26, 2017 , ... After raising nearly $30,000 on Kickstarter ... to be available at a discounted crowdfunding price on Indiegogo . , “Along ... I also wanted to bring a fidget toy to the market that was made ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
(Date:5/6/2017)...  Hill-Rom Holdings, Inc. (NYSE: HRC), has begun a ... to its Welch Allyn campus. The ... more than 100 new jobs to Central ... a significant presence for more than 100 years. Hill-Rom,s ... large portion of which will be R&D and engineering ...
Breaking Medicine Technology: